Evidence map›Paper›PMID 33610939›Full record

ReviewCurrent opinion in chemical biology2021

Understanding and controlling amyloid aggregation with chirality.

Alejandro R Foley, Jevgenij A Raskatov

Abstract readReview
In one paragraph

Review in Current opinion in chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Chirality Makes or Breaks Chemically Driven Self-Assembly.Angewandte Chemie (International ed. in English) · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alejandro R FoleyDepartment of Chemistry and Biochemistry, University of California Santa Cruz, Santa Cruz, CA, 95064, USA.
Jevgenij A RaskatovDepartment of Chemistry and Biochemistry, University of California Santa Cruz, Santa Cruz, CA, 95064, USA. Electronic address: jraskato@ucsc.edu.

Funding

UNIVERSITY OF CALIFORNIA, SANTA CRUZ IMSD PROGRAMR25GM058903 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI JURICA, MELISSA S · 1999 to 2019
$12.2M
Using Chirality to Understand and Control Amyloid Beta Neuronal Uptake and ToxicityR01AG074954 · NIA · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI Jevgenij Raskatov · 2022 to 2026
$1.9M
Chiral Inactivation of Amyloid beta Actions in Cytotoxicity, Synaptic transmission and PlasticityR21AG058074 · NIA · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI RASKATOV, JEVGENIJ · 2017 to 2018
$430k
NIA NIH HHS R01 AG074954NIA NIH HHS R21 AG058074NIGMS NIH HHS R25 GM058903
6 · The paper itself

Abstract

Amyloid aggregation and human disease are inextricably linked. Examples include Alzheimer disease, Parkinson disease, and type II diabetes. While seminal advances on the mechanistic understanding of these diseases have been made over the last decades, controlling amyloid fibril formation still represents a challenge, and it is a subject of active research. In this regard, chiral modifications have increasingly been proved to offer a particularly well-suited approach toward accessing to previously unknown aggregation pathways and to provide with novel insights on the biological mechanisms of action of amyloidogenic peptides and proteins. Here, we summarize recent advances on how the use of mirror-image peptides/proteins and d-amino acid incorporations have helped modulate amyloid aggregation, offered new mechanistic tools to study cellular interactions, and allowed us to identify key positions within the peptide/protein sequence that influence amyloid fibril growth and toxicity.

Indexed as

AmyloidDiabetes Mellitus, Type 2Amino Acid SequenceAmyloid beta-PeptidesHumansPeptidesAmyloidAmyloid beta-PeptidesPeptidesAmyloidChiralityMirror-image peptidesModulation of aggregation pathways

Identifiers

PMID33610939
PMCPMC8368077

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.